Financial Results nine Month period 2019

Pillars of growth

R&D

Heavy bet for R&D
as a future
growth engine

conocer +

R&D&i
R&D

Heavy bet on R&D
as a future
growth engine

find out more

R&D&i
Biosimilar de Enoxaparina

Biosimilars

A great growth opportunity for ROVI in a market that totals more than 1,000 million euros in Europe.

find out more

Especialidades farmacéuticas

Pharmaceutical products

Diversified portfolio of innovative own and licensed products protected by patents.
 

find out more

Bemiparina

Low Molecular Weight Heparin

ROVI's principal product, a low-molecular-weight heparin developed in-house.
 

find out more

Fabricación a terceros

Contract manufacturing

High production capacity with four manufacturing plants for prefilled syringes and oral solid forms.

find out more

Rovi en cifras

Rovi in figures

+19%

Net profit of the business without R&D in 2018

+42%

2018 LMWHglobal sales

56 countries

Bemiparim international presence  with 22 international partners

6 plants

for manufacturing own and third-party products in Spain

€32,4 Mn

of investment in R&D in 2018 Commitment to innovation

7 countries

Direct presence through subsidiaries  to market Enoxaparin

Information for investors

Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.

Go to Shareholders and Investors

 

Last news on Rovi 

(See all items)

0

25/11/2019

2019 Investor Day presentation

ROVI updates its strategy in a meeting with shareholders, investors and analysts.

0

25/11/2019

Financial Results Nine month period 2019 - Video

Javier López-Belmonte, Vicepresident and CFO of Laboratorios Farmacéuticos ROVI presents the financial results for the first nine months of 2019.

Last annual report

annualreport1

Annual Report 2017

Last regular
public information

annualreport1

Financial Results Nine month period 2019 - Video